Dx Deals: New Deal Expands Reach of Oral Cancer Test to Dental Practices
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
An effective business case communicates need, benefit, and risks.
Abbott and Roche garnered the lion’s share of new 510(k) lab test approvals in 2022.
There were three notable CDx alliances announced in January 2023, all of which involved cancer-related solutions.
According to a new report, tough macro-economic conditions caused digital health fundraising levels to fall off dramatically in 2022.
Factors to consider when determining if the concierge business model is best for your laboratory.
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.
Here are what G2 Intelligence considers to be the 10 most significant FDA lab testing clearances of 2022, in rough chronological order.
Here’s an approach to ensure your lab patients have the most positive financial experience possible.
The total market for PCR products will likely top $5 billion in 2023, according to a new report.